Therapeutic Potential of Targeting the Endocannabinoids: Implications for the Treatment of Obesity, Metabolic Syndrome, Drug Abuse and Smoking Cessation
Sonia Tucci(University of Liverpool), T H Kirkham(University of Liverpool), Joanne A. Harrold, Jason C. G. Halford(University of Liverpool)
Cited by 58
Related Papers
Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase
|Journal of Biological Chemistry|2005|469
Television Food Advertising to Children: A Global Perspective
|American Journal of Public Health|2010|422
The cannabinoid CB<sub>1</sub> receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin
|British Journal of Pharmacology|2004|184
Nicotinic–serotonergic interactions in brain and behaviour
|Pharmacology Biochemistry and Behavior|2002|149
The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
|Diabetes Metabolic Syndrome and Obesity|2010|146